Zylo Therapeutics (fka )

[Ubertino]

https://www.panaceanano.com/

Management

Dr. Youssry Botros is a co-founder and the Chief Executive Officer of PanaceaNano Inc. Prior to founding PanaceaNano Inc, he spent 16 years at Intel Corporation where he focused on Nano-scale material systems and their emerging applications, such as beyond CMOS electronics, ultra-low power information processing, bio-inspired computing, energy generation, storage, and harvesting, Organic Photovoltaics, Organic Functional Systems, Silicon Photonics, low energy displays, and wearables. He founded and managed many Intel collaborations in these areas. He founded and chaired the SEMI International Process Control Systems Task Force (PCS-TF) with tens of global companies semiconductor participating. PCS-TF defined the PCS SEMI Standards (known as E133). Youssry published more than 60 papers in top journals and magazines (including Science and Nature), more than 200 conference papers, 4 book chapters, 3 patents and made numerous presentations to different industrial and academic forums. Youssry got his Ph.D. from the University of Michigan, Ann Arbor in 1998 and his M.Sc. and B.Sc. from Alexandria University in 1993 and 1990, respectively.

Sir Fraser Stoddart is a co-founder and the Chief Technology Officer of PanaceaNano Inc. He is one of the few chemists of the past quarter of a century to have created a new field of organic chemistry — namely, one in which the mechanical bond is a pre-eminent feature of molecular compounds. He has pioneered the development of the use of molecular recognition and self-assembly processes in template-directed protocols for the syntheses of two-state mechanically interlocked compounds (bistable catenanes and rotaxanes) that have been employed as molecular switches and as motor-molecules in the fabrication of nanoelectronic devices and NanoElectroMechanical Systems (NEMS).

His work has been recognized by many awards, including the Nobel Prize in Chemistry (2016), the American Chemical Society’s Cope Award (2008), the Royal Society's Davy Medal (2008), the King Faisal International Prize in Science (2007), the Tetrahedron Prize for Creativity in Organic Chemistry (2007), the Albert Einstein World Award of Science (2007), the Foresight Nanotech Institute Feynman Prize in Nanotechnology (Experimental) (2007), the Nagoya Gold Medal in Organic Chemistry (2004), the American Chemical Society’s Cope Scholar Award (1999), the International Izatt-Christensen Award in Macrocyclic Chemistry (1993), and the Carbohydrate Chemistry Award of The Chemical Society (1978). He is currently on the international advisory boards of numerous journals, including Chemistry World, ChemPlusChem, Macromolecular Rapid Communications and Organic Letters. He is editor-in-chief of Applied Nanoscience. He is a Fellow of the Royal Society (1994), the German Academy (Leopoldina) of Natural Sciences (1999), the American Association for the Advancement of Science (2005), and the Science Division of the Royal Netherlands Academy of Arts and Sciences (2006). He is a member of the American Academy of Arts and Sciences (2012) and the National Academy of Sciences (2014). He is an honorary fellow of the Royal Society of Edinburgh (2008) and the Royal Society of Chemistry (2011). He was appointed by Her Majesty Queen Elizabeth II as a Knight Bachelor in her 2007 New Year’s Honours List for his services to chemistry and molecular nanotechnology. In 2010 he was the recipient of a Royal Medal, granted by Her Majesty Queen Elizabeth II, and presented by Prince Philip, Duke of Edinburgh, at the Royal Society of Edinburgh.

Samer Taha, Ph.D.
Vice President of Business Development
Grey LinkedIn Icon
Grey Twitter Icon
Dr. Samer Taha is the Vice President of Business Development at PanaceaNano Inc. He oversees expanding PanaceaNano’s business alliances and commercial opportunities. Dr. Samer is also founder and CEO of Waseela for Integrated ICT Solutions (www.waseela.com), a regional master system integrator specialized in advanced wireless and ICT solutions that has deployed and integrated thousands of networking and ICT systems since its establishment. He is also a board member at Dar Al Hai, www.daralhai.com, a regional trade and investment group with annual turnover of more than USD 1.2 Billion in 2016. Between 1999 and 2002, Samer was a member of the CICTR Lab (http://cictr.ee.psu.edu) at the Pennsylvania State University where he got his Ph.D. in Electrical Engineering in 2002. Then he joined Intel Corporation in 2002 where he worked as a senior research engineer and R&D manager for 5 years in next-generation silicon wafer processing technologies and embedded wireless systems, during which he published 4 patents. He later founded Waseela in 2007 and focused more on the business development and commercial consultations services, he participated in numerous industry conferences as a speaker and industry leader. Samer got his B.Sc. in Electrical Engineering from the Jordan University of Science & Technology in 1998.

Benjie Limketkai, Ph.D.
Director of Platform Development
Benjie Limketkai is the director of platform development for PanaceaNano Inc. He leads the execution of technology strategy and overseas platform development and integration of the various technologies and intellectual property created. He has over 10 years of industry experience in nanotechnology. Prior to joining PanaceaNano Inc, he worked at Intel Corporation in the process technology development for Intel's 14nm and 7nm nodes. He was the lead research scientist for organic nanotechnology research at Intel Labs and engaged in collaboration with multiple universities. He received his Ph.D. in Electrical Engineering from the Massachusetts Institute of Technology and his B.S. from the California Institute of Technology.

https://www.panaceanano.com/management

[Ubertino]

ABOUT NOBLE


NOBLE, the most advanced and high-tech luxury anti-aging skin care product line for women, is the culmination of research developed by Sir Fraser Stoddart, company Co-founder and Chief Technology Officer.

HISTORY
Dr. Youssry Botros (Former Nanotechnology Research Director at Intel Corp.) and Sir Fraser Stoddart (2016 Nobel Prize Winner in Chemistry) co-founded PanaceaNano, a company that focuses on commercializing high performance, highly customized nano-delivery customized skin care platforms. PanaceaNano patented technology is based on a new class of porous, bio-degradable, Organic Nano-Cube (“ONC”) hollow crystals for encapsulation and controlled delivery skin care applications. PanaceaNano developed formulations that improve the delivery of active ingredients. The technology releases ingredients directly into the skin at a controlled rate for long-lasting treatment without the side effects of skin irritation resulting from uncontrolled exposure. PanaceaNano is launching its first set of anti-aging products under the NOBLE brand, which will mark the first time ever for consumers to experience products based on the novel ONC nanotechnology.

INNOVATION
The method of delivery of the active ingredient of a topical cosmetic formulation determines the efficacy of the product. PanaceaNano developed and patented platforms and proprietary formulations for Organic Nano-Cube (ONC) based skin care that can host and store active ingredients for anti-aging skin care products that will significantly improve their effectiveness and benefits. ONC stores and releases the ingredients at the molecular level and directly delivers them into the skin at a controlled rate for long-lasting treatment.

ONC formulated into topical skin care products have shown higher cumulative release of ingredients into the skin at a steady release rate that can provide much longer anti-aging effect than other products. Other nano-particle formulations do not exhibit the same performance enhancement as NOBLE ONC technology. The major factor that improves the effectiveness of an anti-aging product is how well and how long these ingredients penetrate the consumers’ skin. The technological improvements in anti-aging skin care delivery that PanaceaNano demonstrates boosts the anti-aging skin care product performance.

BIOGRAPHY
Dr. Youssry Botros, Founder and CEO, PanaceaNano
Dr. Botros spent 16 years at Intel Corporation where he focused on and directed research on nano-scale material systems and their emerging applications such as green nano-technologies, among other areas of research. He was assigned by Intel to be the Executive Director of both the Functional Engineered Nano-Architectonics (FENA) Focus Center and the Western Institute of Nano-electronics (WIN). Before being assigned to FENA/WIN, he spent five years at the Microprocessor (Logic) Technology Development Group at Intel, working on Nano-patterning.

Dr. Botros has more than 120 journal papers published in top journals and magazines (including Science and Nature), more than 400 conference papers, 4 book chapters, and 10 patents.

Sir Fraser Stoddart, Co-founder and Chief Technology Officer, PanaceaNano
Winner of the 2016 Nobel Prize in Chemistry, he is an American chemist who is on the Board of Trustees, Professor of Chemistry and head of the Stoddart Mechanostereochemistry Group in the Department of Chemistry at Northwestern University. He works in the area of supramolecular chemistry and nanotechnology. Stoddart was appointed a Knight Bachelor in December 2006 by Queen Elizabeth II.

In 2007, he received the Albert Einstein World Award of Science in recognition of his outstanding and pioneering work in molecular compounds. The list of his other awards, honors and memberships can be provided upon request.

https://noble-skincare.com/about-us

[Ubertino]

Panacea Nano

https://www.panaceanano.com/onc

[Ubertino]

I'm enthralled with the possibilities:

1. A composition for releasing nitric oxide (NO) comprising nitric oxide encapsulated in a matrix of chitosan, polyethylene glycol (PEG), and tetra-methoxy-ortho-silicate (TMOS).

30. A method of treating an infection in a subject comprising administering to the subject an amount of the composition of claim 1 effective to treat the infection, wherein the infection is a bacterial, viral, fungal or parasitic.

https://goo.gl/bz4Lk9

[Ubertino]

Very impressive:

EXECUTIVE TEAM

Scott R. Pancoast, CEO (and Company Founder and Board Member):

Scott Pancoast was CEO and board member of Lpath [NASDAQ:LPTN] from 2005 through 2014 and was Chairman of the company from 1999 through 2010. He evolved this start-up from incubation at San Diego State University to eventual public-company status and raised about $150 million, with more than $50 million coming from non-dilutive government grants and from partnership proceeds. He forged worldwide partnerships with Merck-Serono and Pfizer and attracted equity investments from J&J and Biogen Idec. As EVP of Western States Investment Group from 1994 until 2004, he invested in and managed a portfolio of startups ranging from Endonetics (sold to Medtronic) to Mpex (sold to Axcan) to DermTech (currently in revenue ramp). He has served on over a dozen boards, including three public ones. Mr. Pancoast holds a BA in economics summa cum laude from the University of Virginia and an MBA with honors from Harvard Business School.

Thomas Murray, VP Business Development:

Tom is an executive who has served in several leadership capacities over the years. Tom spent the early part of his career in a large corporation, primarily in sales, operations, and business development. Subsequently, he was one of three principals in a high-tech startup industry bringing a new device to market. In 2000, he landed at a nationwide sanitation services company and served as president of that organization for 13 years. Given that the average account size generated well over $1 million of annual revenues, Tom was the driving force of the business development and strategy functions. In 2013 he was instrumental in the sale of that organization to the largest competitor in that industry. He then served as an executive vice president for three years with that organization, overseeing a $210m operating unit, with about 4,000 employees covering the eastern third of the U.S. Over the last two years, Tom has consulted with two high-tech start-ups on business development and general strategic issues. Tom has a degree in political science from the University of Cincinnati.

Joel M. Friedman, MD, PhD, Scientific Founder and Special Advisor—Basic Research:

Joel Friedman, MD, PhD, is a Professor in the Department of Physiology and Biophysics and the Department of Medicine at the Albert Einstein College of Medicine. He also holds the Young Men’s Division Chair in Cardiovascular Physiology. He is a leading expert in the areas of molecular and protein biophysics, nitric oxide biochemistry, blood substitutes and nanotechnology. Dr. Friedman is the author of over 150 peer-reviewed scientific papers and is the co-inventor of the Nanopod™ delivery system. He has been the principle investigator on several NIH-funded program projects and R01’s. He is the head of the W.M. Keck-funded Biomolecular Laser Spectroscopy facility at the Albert Einstein College of Medicine and is on the selection committee for the Albany Prize. He is currently overseeing the further development and characterization of nanotechnology that is the foundation for new drug delivery and tissue imaging formulations.

Adam Friedman, MD, Scientific Founder and Special Advisor—Translational Research:

Dr. Friedman is Associate Professor of Dermatology and serves as Residency Program Director, Director of Translational Research, and Director of the Supportive Oncodermatology Clinic in the Dept. of Dermatology at The George Washington University School of Medicine. Dr. Friedman is co-inventor of the Nanopod™ delivery system and is currently investigating novel treatments for infectious diseases, wound healing, and endothelial dysfunction. He holds multiple patents and has published over 160 papers/chapters and 2 textbooks. Dr. Friedman completed his undergraduate training at the Univ. of Pennsylvania and graduated with Distinction in Dermatologic Research at the Albert Einstein College of Medicine. During his residency at Einstein, he was appointed Chief Resident. He then joined the Einstein faculty, during which time he was the Director of Dermatologic Research, Director of the Translational Research Fellowship, and the Associate Program Director. Dr. Friedman lectures extensively in both national and international forums, and serves on a number of committees and advisory boards. He is a dermatology expert for healthguru.com, everydayhealth.com, and the Huffington Post, and hosts the online series titled “Ask an Expert” and the Journal of Drugs in Dermatology Podcast, “Ask an Investigator.”

http://www.zylotherapeutics.com/team.html